secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2022-12-21T23:59:59+00:00
Accession:  0001193125-22-309581
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz exercises zanidatamab option; pays $325M; 41.3% ORR in BTC trial
---------------------------------------------------------------------

- Jazz exercised option to retain exclusive rights to zanidatamab in U.S., Europe, and Japan.
- One-time $325M payment in Q4 2022; total potential milestones up to $1.76B plus royalties.
- Pivotal HERIZON-BTC-01 trial showed 41.3% ORR (95% CI: 30.4-52.8) and median DOR 12.9 months.
- Safety profile consistent with prior monotherapy; no new safety signals.
- Zymeworks eligible for tiered royalties of 10-20% on Jazz net sales pending approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312522309581/0001193125-22-309581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312522309581/d439594d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-309581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer